Company profile

Beximco Group

Bangladeshi conglomerate founded in 1972 by the Rahman brothers; most units are under a court-ordered receiver, but Beximco Pharma stays profitable.

  • Conglomerate: pharmaceuticals, textiles and garments, ceramics, energy, media
  • Dhaka, Bangladesh
  • Listed units on the Dhaka Stock Exchange (Beximco Pharma also on London AIM); most group companies under a court-ordered receiver since 2024

At a glance

Founded
1972
Headquarters
Dhaka, Bangladesh
Industry
Conglomerate: pharmaceuticals, textiles and garments, ceramics, energy, media
Status
Listed units on the Dhaka Stock Exchange (Beximco Pharma also on London AIM); most group companies under a court-ordered receiver since 2024

Founders and key people

Founders

Leadership

  • S. M. Rabbur RezaManaging Director, Beximco Pharmaceuticals (from November 2026)

Company timeline

Key milestones in Beximco Group’s history.

  1. 1972

    Founded in newly independent Bangladesh

    Brothers A. S. F. Rahman and Salman F. Rahman set up Bangladesh Export Import Company.

  2. 1976

    Beximco Pharmaceuticals founded

    It grows into one of the country's leading generic-drug makers and exporters.

  3. 1982

    The brothers co-found AB Bank

    One of Bangladesh's first private-sector banks.

  4. 2005

    Beximco Pharma lists on London's AIM

    The first Bangladeshi company to do so.

  5. 2019

    Salman F. Rahman becomes Sheikh Hasina's industry adviser

    A cabinet-rank post he held while vice-chairman of the group.

  6. 2021

    Beximco Pharma distributes Covishield vaccines

    And completes its purchase of Sanofi's Bangladesh business.

  7. August 2024

    Hasina falls; Salman F. Rahman arrested

    Detained on 13 August 2024 in cases that remain unproven.

  8. 2024–2025

    Courts put the group under a receiver

    The High Court ordered a receiver for group assets; the Appellate Division upheld it but carved out Beximco Pharmaceuticals.

  9. 2025

    Government moves to close 12 group companies

    And to sell mortgaged Beximco Pharma and Shinepukur shares to pay workers' dues.

  10. September–October 2026

    Salman F. Rahman removed from listed boards

    Regulator-approved boards at Beximco Pharma, BEXIMCO Limited and Shinepukur Ceramics leave him off.

The company story

Overview

Beximco was, for most of Bangladesh's independent history, the country's best-known private conglomerate. It made generic medicines, spun yarn and sewed garments for Western brands, fired ceramics, built power plants and owned a television channel and a newspaper. Today it is two very different businesses under one name. Beximco Pharmaceuticals, listed in Dhaka and on London's AIM, still runs profitably. Most of the rest of the group has been under a court-ordered receiver since the fall of Sheikh Hasina's government in 2024, with factories shut and tens of thousands of jobs gone.

The company is inseparable from its co-founder Salman F. Rahman, who was both its vice-chairman and, from 2019 to 2024, the prime minister's cabinet-rank adviser on private industry.

History

The brothers A. S. F. Rahman and Salman F. Rahman founded Bangladesh Export Import Company in 1972, a year after a war of independence had left the new country short of almost everything. Trading came first. Manufacturing followed, and the most important step was Beximco Pharmaceuticals in 1976. Over the next decades it became one of Bangladesh's leading drug makers and one of its few pharmaceutical exporters, and in 2005 it became the first Bangladeshi company listed on London's Alternative Investment Market. In 1982 the brothers co-founded AB Bank, one of the country's first private banks.

The group then spread across the economy: a large vertically integrated textile and apparel business, Shinepukur Ceramics, energy projects, financial services, Independent Television and the English-language daily The Independent. In 2021 Beximco Pharma distributed the Oxford-AstraZeneca vaccine made by the Serum Institute of India under the Covishield name, and completed its purchase of Sanofi's Bangladesh business.

The turn came in August 2024. A student-led uprising forced Hasina from power, and Salman F. Rahman was arrested on 13 August. The High Court then ordered a receiver to take charge of Beximco Group assets because of the group's very large borrowings from state-owned banks. The Appellate Division upheld that order but suspended it for Beximco Pharmaceuticals. In February 2025 Bangladesh Bank executive director Khasru Parvez was named receiver.

How the business works

The healthy part of Beximco earns money the way most generic-drug makers do: it manufactures off-patent medicines in volume and sells them through pharmacies and hospitals at home, with a growing export business. For the year to 30 June 2025 Beximco Pharmaceuticals reported consolidated net revenue of about Tk 49.1 billion, up 10.7%, and net profit of Tk 699.88 crore, according to its results and The Business Standard. It recommended a 47.5% cash dividend.

The rest of the group depended on export garments and on bank credit, and that model has largely stopped. Reporting by The Daily Star and bdnews24.com put garment lay-offs at about 40,000 workers. In 2025 the government moved to close 12 group companies permanently, most of them garment units, and to sell mortgaged shares of Beximco Pharmaceuticals and Shinepukur Ceramics to pay workers' dues. A Tk 3,000 crore green sukuk issued by BEXIMCO Limited, with about Tk 2,800 crore still owed to investors, matures in December 2026; a Bangladesh Bank-led committee has proposed extending it to 2032.

Ownership and leadership

The founding family still holds the controlling stakes, but control in practice is split. A. S. F. Rahman chairs Beximco Pharmaceuticals and, under new boards approved by the securities regulator in 2026, BEXIMCO Limited and Shinepukur Ceramics. Salman F. Rahman was removed from all three listed boards in September and October 2026, reportedly with his consent. On 12 November 2026 Beximco Pharma named its long-time chief operating officer, S. M. Rabbur Reza, managing director, succeeding Iqbal Ahmed. Everything outside the pharmaceutical company answers to the receiver.

Controversies

ALLEGED: corruption, loan fraud and money laundering. Since his arrest Salman F. Rahman has been named in Anti-Corruption Commission loan-fraud cases, including one over Janata Bank lending, and investigators approved charge sheets in 17 money-laundering cases in November 2025 over about $97 million allegedly moved through export trade. None has reached a verdict, and he is entitled to the presumption of innocence.

ALLEGED: crimes against humanity. In January 2026 the International Crimes Tribunal framed charges accusing him of inciting killings during the 2024 uprising. He pleaded not guilty and the trial was continuing in late 2026.

PROVEN: a structural conflict of interest. No court ruling is needed to see the problem the group's critics described for years. A cabinet-rank adviser on industry was also vice-chairman of a conglomerate that borrowed from state banks and held national contracts, including the 2021 vaccine distribution role.

DISMISSED: the 2010–11 market crash. Rahman's name featured in the cases that followed Bangladesh's stock-market collapse, but he was acquitted around 2015.

Why it matters

Beximco shows how much of an industrial empire can rest on access to credit and to power, and how quickly that part unravels when power changes hands. Its pharmaceutical arm, the part built on manufacturing skill and export sales, is also the part still standing. For the full account of the founder's rise and fall, read Salman F. Rahman: Beximco and the Fortune Fused to the State.

Key figures

Beximco Pharmaceuticals consolidated net revenue
About Tk 49.1 billion, up 10.7%
As of Year to 30 June 2025 · Beximco Pharmaceuticals annual results announcement
Beximco Pharmaceuticals consolidated net profit
Tk 699.88 crore (about Tk 7.0 billion)
As of Year to 30 June 2025 · The Business Standard, reporting the company's results
Garment workers laid off across group units
About 40,000
As of 2025 · The Daily Star and bdnews24.com reporting
Group companies the government moved to close permanently
12, mostly export garment units
As of 2025 · bdnews24.com
Beximco green sukuk outstanding
About Tk 2,800 crore, due December 2026; a six-year extension to 2032 proposed
As of July 2026 · The Business Standard reporting

Quick answers about Beximco Group

Who owns Beximco Group?
Beximco is controlled by the family of its two founders, the brothers A. S. F. Rahman and Salman F. Rahman, alongside public shareholders in its listed companies. Since 2024 most group companies have been run by a receiver appointed through Bangladesh Bank under a court order, while Beximco Pharmaceuticals kept its own board.
Who founded Beximco?
Beximco was founded in Dhaka in 1972, a year after Bangladesh's independence, by A. S. F. Rahman and his younger brother Salman F. Rahman. The name stands for Bangladesh Export Import Company. The brothers later added pharmaceuticals in 1976 and co-founded AB Bank in 1982.
What happened to Beximco?
After Sheikh Hasina's government fell in August 2024, Salman F. Rahman was arrested and courts placed most of the group under a receiver over its large bank debts. About 40,000 garment workers lost their jobs and the government moved to close 12 companies. The criminal cases against Rahman have not reached verdicts.
Is Beximco Pharmaceuticals still operating?
Yes. Beximco Pharmaceuticals was excluded from the receivership and stayed profitable, reporting net profit of about Tk 7 billion for the year to June 2025. Its London AIM trading was suspended in January 2026 over late accounts, and a new regulator-approved board and managing director followed in 2026.

Our coverage

HustleMemo stories on Beximco Group.

Salman F. Rahman, co-founder of Beximco, subject of a case study on business and political power in Bangladesh.
industry18 min read

Salman F. Rahman: Beximco and the Fortune Fused to the State

Salman F. Rahman co-founded the Beximco conglomerate and became Sheikh Hasina’s cabinet-rank industry adviser. A sourced, critically neutral look at genuine industrial achievement, the structural conflict of political proximity, a 2015 acquittal, and the unproven charges that followed Hasina’s 2024 fall.

Sources

  1. Beximco Group: official website (opens in a new tab)
  2. Beximco Pharmaceuticals: official website and investor information (opens in a new tab)
  3. Beximco Pharmaceuticals, half-year and annual results announcements on the London Stock Exchange RNS, 2025–2026
  4. The Business Standard, 'Beximco Pharma declares 47.5% cash dividend, makes Tk699.88cr profit in FY25'
  5. The Business Standard, 'Appellate Div upholds HC decision to appoint receiver at Beximco'
  6. The Financial Express (Dhaka), 'Bangladesh Bank's Khasru Parvez appointed as new Beximco receiver', February 2025
  7. bdnews24.com, 'Govt to close down 12 Beximco companies, sell mortgage shares of Pharma, Shinepukur', 2025
  8. The Financial Express (Dhaka), 'Salman F Rahman removed from boards of listed Beximco Group firms', October 2026
  9. The Financial Express (Dhaka), 'Beximco Pharma appoints Rabbur Reza as new MD', 12 November 2026
  10. BSS, 'ICT indicts Salman, Anisul for July crimes against humanity', 12 January 2026

Last updated:

More companies

Browse all companies